SG Americas Securities LLC decreased its position in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 59.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,466 shares of the life sciences company’s stock after selling 29,630 shares during the quarter. SG Americas Securities LLC’s holdings in Integra Lifesciences were worth $1,348,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. FMR LLC lifted its holdings in Integra Lifesciences by 11.8% in the 2nd quarter. FMR LLC now owns 11,078,120 shares of the life sciences company’s stock worth $713,542,000 after purchasing an additional 1,166,483 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Integra Lifesciences by 22.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,966,341 shares of the life sciences company’s stock worth $126,652,000 after purchasing an additional 365,254 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Integra Lifesciences by 2.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 744,153 shares of the life sciences company’s stock worth $47,931,000 after purchasing an additional 17,431 shares during the last quarter. Millennium Management LLC acquired a new stake in Integra Lifesciences in the 2nd quarter worth approximately $46,263,000. Finally, OppenheimerFunds Inc. lifted its holdings in Integra Lifesciences by 30.8% in the 2nd quarter. OppenheimerFunds Inc. now owns 604,315 shares of the life sciences company’s stock worth $38,924,000 after purchasing an additional 142,321 shares during the last quarter. 85.94% of the stock is owned by institutional investors and hedge funds.
Shares of IART stock opened at $50.99 on Friday. Integra Lifesciences Holdings Corp has a 12 month low of $45.96 and a 12 month high of $67.50. The company has a market cap of $4.39 billion, a PE ratio of 26.28, a price-to-earnings-growth ratio of 1.60 and a beta of 0.76. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.20 and a quick ratio of 2.08.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, hitting analysts’ consensus estimates of $0.59. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The company had revenue of $365.85 million during the quarter, compared to analyst estimates of $367.89 million. During the same period in the previous year, the company earned $0.45 earnings per share. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. Equities analysts anticipate that Integra Lifesciences Holdings Corp will post 2.39 earnings per share for the current fiscal year.
Several research firms recently weighed in on IART. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a report on Tuesday, October 2nd. Zacks Investment Research lowered Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 25th. BTIG Research restated a “buy” rating and issued a $69.00 target price on shares of Integra Lifesciences in a report on Wednesday, September 12th. BidaskClub upgraded Integra Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, October 19th. Finally, Morgan Stanley set a $68.00 target price on Integra Lifesciences and gave the stock a “hold” rating in a report on Thursday, October 11th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company. Integra Lifesciences presently has an average rating of “Hold” and an average target price of $61.62.
In other news, major shareholder Richard E. Caruso sold 46,676 shares of the company’s stock in a transaction that occurred on Wednesday, October 17th. The stock was sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the completion of the transaction, the insider now directly owns 134,134 shares in the company, valued at $8,475,927.46. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Barbara B. Hill bought 3,705 shares of the business’s stock in a transaction that occurred on Monday, November 5th. The stock was purchased at an average price of $53.90 per share, with a total value of $199,699.50. Following the completion of the purchase, the director now directly owns 63,381 shares of the company’s stock, valued at approximately $3,416,235.90. The disclosure for this purchase can be found here. 5.10% of the stock is owned by insiders.
WARNING: “SG Americas Securities LLC Sells 29,630 Shares of Integra Lifesciences Holdings Corp (IART)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/12/07/sg-americas-securities-llc-sells-29630-shares-of-integra-lifesciences-holdings-corp-iart.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: What is a capital gain?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.